Is Kwality Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kwality Pharmaceuticals Ltd is a average quality company .

Is Kwality Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Kwality Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Kwality Pharmaceuticals share price return in the past 10 years?

Data is not available for this company

Is Kwality Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kwality Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Kwality Pharmaceuticals?

The latest standalone P/E ratio of Kwality Pharmaceuticals as of 03-Dec-2024 is 31.63.

What is the P/B ratio of Kwality Pharmaceuticals?

The latest standalone P/B ratio of Kwality Pharmaceuticals as of 03-Dec-2024 is 3.80.

What is the 52-week high and low of Kwality Pharmaceuticals?

The 52-week high of Kwality Pharmaceuticals is Rs. 961.15 and the 52-week low is Rs. 356.10.

Kwality Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Kwality Pharmaceuticals
Brand: Kwality Pharmaceuticals

BSE: 539997 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Kwality Pharma Share Price

₹899.50 13.80 1.56%
as on 03-Dec'24 16:59

10 Year X-Ray of Kwality Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.7%	14%	19.5%	19.4%	21.5%	18.5%	26.5%	97.2%	12.3%	13.6%	-
Value Creation Index ⓘ	-0.2	-0	0.4	0.4	0.5	0.3	0.9	5.9	-0.1	0.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	52.4	75.9	95.3	137	165	139	262	456	251	307	340
Sales YoY Gr.	-	44.9%	25.6%	43.6%	20.7%	-16%	88.6%	74.4%	-45%	22.4%	-
Adj EPS ⓘ	1.3	2.1	3.7	4.5	7.3	8	14.6	114.6	29	27.9	28
YoY Gr.	-	63.4%	73.8%	19.9%	63%	9.4%	83.9%	683.7%	-74.7%	-3.8%	-
BVPS (₹) ⓘ	21.4	21.6	24.6	29.2	36.5	44.6	59.5	175.2	193.9	217	233.2
Adj Net Profit ⓘ	1.3	2.2	3.9	4.6	7.5	8.3	15.2	119	30.1	29	29
Cash Flow from Ops. ⓘ	0.6	-2.6	4	-0.1	13	5.6	26.4	59.2	42.2	43.4	-
Debt/CF from Ops. ⓘ	12.8	-5	4.7	-275.3	2.2	6.2	1.6	0.9	2.1	2.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	21.7%	13.2%	5.5%	22.4%
Adj EPS ⓘ	40.5%	30.9%	24.1%	-3.8%
BVPSⓘ	29.3%	42.9%	54%	11.9%
Share Price	-	107.7%	-0.2%	134.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	7	10.2	15.8	16.1	21.6	19.2	27.7	97	15.7	13.5	12.4
Op. Profit Mgn % ⓘ	7	7.6	9.6	8.4	9.2	10.2	11.2	37.7	24.3	21.7	21.9
Net Profit Mgn % ⓘ	2.5	2.8	4.1	3.4	4.6	6	5.8	26.1	12	9.4	8.5
Debt to Equity ⓘ	0.4	0.6	0.7	0.9	0.7	0.8	0.7	0.3	0.5	0.4	0.1
Working Cap Days ⓘ	151	139	157	155	154	203	126	129	319	276	120
Cash Conv. Cycle ⓘ	60	69	78	69	63	78	36	33	141	151	49

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 24.07%

Sales growth is good in last 4 quarters at 30.27%

Return on Equity has declined versus last 3 years average to 12.40%

Sales growth has been subdued in last 3 years 5.51%

Latest Financials - Kwality Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	28	27.8
TTM Sales (₹ Cr.)	340	340
BVPS (₹.) ⓘ	233.2	231.5
Reserves (₹ Cr.) ⓘ	232	230
P/BV ⓘ	3.80	3.83
PE ⓘ	31.63	31.82

From the Market
52 Week Low / High (₹)	356.10 / 961.15
All Time Low / High (₹)	20.43 / 1117.00
Market Cap (₹ Cr.)	919
Equity (₹ Cr.)	10.4
Face Value (₹)	10
Industry PE ⓘ	44.7

Management X-Ray of Kwality Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kwality Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Kwality Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	52	76	95	137	165	139	262	456	251	307
Operating Expenses ⓘ	49	70	87	125	150	125	232	284	190	241
Manufacturing Costs	3	4	5	8	7	8	13	79	63	93
Material Costs	39	58	70	102	119	87	166	142	69	90
Employee Cost	2	2	4	5	8	11	14	19	28	30
Other Costs ⓘ	5	6	8	11	16	19	39	44	30	28
Operating Profit ⓘ	4	5	9	11	15	14	29	172	61	67
Operating Profit Margin (%)	6.9%	7.1%	9.0%	8.4%	9.2%	10.2%	11.2%	37.6%	24.3%	21.7%
Other Income ⓘ	1	1	2	1	1	4	2	4	3	2
Interest ⓘ	1	1	2	2	2	3	3	3	7	10
Depreciation ⓘ	1	2	2	3	3	4	6	11	15	20
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	-17	-7
Profit Before Tax ⓘ	2	3	6	8	11	11	22	162	26	31
Tax ⓘ	1	1	2	3	3	3	6	42	6	7
Profit After Tax	1	2	3	5	8	8	15	120	19	24
PAT Margin (%)	2.5%	2.5%	3.6%	3.4%	4.6%	6.1%	5.9%	26.3%	7.8%	7.8%
Adjusted EPS (₹)	1.5	1.9	3.3	4.5	7.3	8.1	14.9	115.7	18.8	23.1
Dividend Payout Ratio (%)	0%	0%	9%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	20	23	26	31	39	47	63	183	202	226
Share Capital ⓘ	4	5	5	10	10	10	10	10	10	10
Reserves ⓘ	15	18	21	21	28	37	52	172	192	216
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	7	12	18	25	26	31	35	43	78	86
Long Term Debt	1	3	3	4	7	10	18	20	27	20
Short Term Debt	7	10	15	21	19	21	16	23	51	66
Trade Payables	4	10	13	22	17	23	26	35	35	44
Others Liabilities ⓘ	7	8	15	19	26	33	45	82	41	42
Total Liabilities ⓘ	38	52	72	98	107	134	169	343	357	398
Fixed Assets
Gross Block	22	21	27	31	40	61	81	127	169	205
Accumulated Depreciation	10	10	12	15	18	20	25	36	49	69
Net Fixed Assetsⓘ	11	11	14	15	22	42	56	91	120	137
CWIP ⓘ	0	0	1	4	6	0	3	12	14	0
Investmentsⓘ	4	5	7	9	8	8	9	4	4	4
Inventories	6	9	14	15	11	22	17	53	86	78
Trade Receivables	9	20	23	37	39	30	38	71	73	116
Cash Equivalents	1	1	2	1	0	1	5	11	6	5
Others Assetsⓘ	7	7	11	17	20	31	41	101	53	58
Total Assets ⓘ	38	52	72	98	107	134	169	343	357	398

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	1	-3	4	0	13	6	26	59	42	43
PBT ⓘ	2	3	6	8	11	11	22	162	26	31
Adjustment ⓘ	2	3	4	5	5	6	9	14	21	37
Changes in Working Capital ⓘ	-3	-7	-4	-9	1	-9	2	-75	2	-23
Tax Paid ⓘ	-1	-1	-2	-3	-3	-3	-6	-41	-6	-1
Cash Flow From Investing Activity ⓘ	-1	-2	-7	-6	-12	-17	-23	-63	-48	-26
Capex	-1	-2	-7	-6	-12	-18	-23	-55	-46	-26
Net Investments	0	0	-1	0	-1	1	0	0	0	0
Others ⓘ	0	0	0	1	1	0	0	-8	-3	-1
Cash Flow From Financing Activityⓘ	1	5	5	5	-2	12	1	6	1	-17
Net Proceeds from Shares ⓘ	0	2	1	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	2	1	1	3	3	10	9	7	-7
Interest Paid ⓘ	-1	-1	-2	-2	-2	-2	-3	-3	-6	-10
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	3	3	5	6	-3	12	-7	0	0	0
Net Cash Flow ⓘ	0	0	1	-1	-1	1	4	2	-5	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	7.39	9.3	14.58	16.76	22.17	20.05	28.55	98.61	10.17	11.25
ROCE (%)	11.72	13.98	19.51	19.37	21.47	18.53	26.51	97.19	12.28	13.62
Asset Turnover Ratio	1.43	1.68	1.53	1.61	1.61	1.15	1.72	1.78	0.72	0.81
PAT to CFO Conversion(x)	1	-1.5	1.33	0	1.63	0.75	1.73	0.49	2.21	1.79
Working Capital Days
Receivable Days	55	69	81	80	84	91	48	43	105	112
Inventory Days	48	36	43	38	29	44	28	28	102	98
Payable Days	54	43	59	62	60	84	54	78	183	162

Kwality Pharmaceuticals Ltd Stock News

Kwality Pharmaceuticals Ltd FAQs

What is the share price of Kwality Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Kwality Pharma on 03-Dec-2024 16:59 is ₹899.5.

What is the market cap of Kwality Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Kwality Pharma stood at ₹919.0.

What is the P/E ratio of Kwality Pharma?

The latest P/E ratio of Kwality Pharma as of 03-Dec-2024 16:59 is 31.63.

What is the P/B ratio of Kwality Pharma?

The latest P/B ratio of Kwality Pharma as of 03-Dec-2024 16:59 is 3.80.

What is the 52-week high and low of Kwality Pharma?

The 52-week high of Kwality Pharma is ₹961.1 and the 52-week low is ₹356.1.

What is the TTM revenue of Kwality Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kwality Pharma is ₹340.2 ( Cr.) .

About Kwality Pharmaceuticals Ltd

The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.

The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization).

Milestones